Roche to pay $42 million to Ascidian to make RNA exon editing drugs
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Israelâs Teva Pharmaceuticals has sued US-based Corcept Therapeutics and Optime Care Inc., a specialty pharma, for monopolising the market for a drug used to.
Researchers co-led by the US-based National Cancer Institute have found genetic variants in women that may play a role in promoting abnormal blood.
AstraZenecaâs oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.
The US drug regulator has granted accelerated approval for a drug to treat chronic inflammatory liver disease to Genfit, headquartered in Nord, France,.
The advisory committee of the US Food and Drug Administration has rejected a therapy using party drug MDMA, or ecstasy or molly to.
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
A dairy farm worker in Michigan, US, has been infected with highly pathogenic avian influenza from sick cows âthe third such case in America.
HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.
HQ Team April 20, 2024: A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less.